Feb. 29, 2008 | Vol. 2 No. 9
After receiving its second warning letter in nine months about its orthopedic implant manufacturing operations, Stryker is linking 25 percent of its 2008 executive bonuses to resolving the issues.
Hospital bed maker Hill-Rom has been cited for its handling of a field correction of latches, according to an FDA warning letter.
Quality assurance managers are advised to become more proactive in handling investigations of pharmaceutical production deviations.
GlaxoSmithKline [GSK] will lay off about 70 employees at its Zebulon manufacturing plant, including production workers and office support staff.
Drug manufacturer Glenmark pharmaceuticals on Thursday said it has got the approval of its shareholders to hive off its generic and active pharmaceutical ingredients (API) into a separate entity.
Jubilant Organosys, India's largest custom research and manufacturing services (CRAMS) provider, has scored new contracts to the tune of $92 million for the year thus far as its business continues to gather momentum.
Dutch biopharmaceutical firm Genmab A/S has agreed to pay $240 million to acquire an antibody manufacturing facility owned by PDL BioPharma Inc. in suburban Minneapolis, Minn.
Pfizer Inc. has reduced its manufacturing work force in Groton over the past few months to a small crew that will close the plant and has transferred all its projects to other global facilities.
After strengthening its foothold on the home turf, active pharmaceutical ingredient (API) manufacturer Arch Pharmlabs is looking for takeovers in matured European markets to spur revenues … by 2010.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.